Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE AND TIMOLOL MALEATE versus KERLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE AND TIMOLOL MALEATE versus KERLONE.
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE vs KERLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brimonidine tartrate is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol maleate is a non-selective beta-adrenergic receptor antagonist that decreases aqueous humor production by blocking beta-2 receptors in the ciliary epithelium.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
One drop in the affected eye(s) twice daily (approximately 12 hours apart).
10 mg orally once daily; may increase to 20 mg once daily if needed. Maximum 20 mg/day.
None Documented
None Documented
Brimonidine: ~2.9 hours (terminal) after ophthalmic administration. Timolol: ~4 hours (terminal); clinically, systemic exposure is low due to topical route.
Terminal elimination half-life is 8-12 hours in healthy adults; may extend to 15-20 hours in renal impairment (CrCl <30 mL/min).
Brimonidine: ~74% renal (unchanged and metabolites), ~22% fecal. Timolol: ~20% renal (unchanged), ~80% hepatic metabolism with biliary and fecal elimination.
Primarily renal excretion of unchanged drug and metabolites (70-80% unchanged; 20-30% as glucuronide or sulfate conjugates). Biliary/fecal excretion accounts for less than 5%.
Category A/B
Category C
Beta-Blocker
Beta-Blocker